Experience of conducting high dose chemotherapy and autologous stem cell transplantation for adult patients at the National Cancer Institute of Ukraine
Kushchevyi E.V., Filonenko K.S., Martynchyk A.V., Kriachok I.A.
Summary. The article provides a brief historical overview of the use of high-dose chemotherapy (HDCT) as a part of treatment of multiple myeloma and lymphoma. The article presents the results of the most important clinical trials evaluating the effectiveness of this therapy in various lymphoproliferative diseases, which allow us to consider this method of treatment as the gold standard for the first-line treatment of multiple myeloma and as the most effective therapy in patients with refractory or recurrent forms of lymphoma, including Hodgkin’s lymphoma and diffuse large В-cell lymphoma. There are also data regarding the use of HDCT in the unfavorable course of Ewing Sarcoma. Based on the European Bone Marrow Transplant Association recommendations, approximate needs for this method in Ukraine are outlined. The results of treatment efficacy and complications of 36 patients with recurrent and refractory Hodgkin’s lymphoma and non-Hodgkin’s lymphoma, primary multiple myeloma and high-risk Ewing sarcoma who have received HDCT with autologous stem cell transplantation in the Department of Oncohematology of the National Cancer Institute with follow up period more than 100 days were presented.
Leave a comment